Eledon up on positive data from ALS therapy study

Eledon Pharmaceuticals

31/05/2022 12:23

** Shares of Eledon Pharmaceuticals  ELDN.O  rise 6.4% to
$3.80 premarket
    ** Co says its experimental monoclonal antibody,
tegoprubart, met main goal of safety and tolerability in a
mid-stage trial in patients with amyotrophic lateral sclerosis
(ALS)  urn:newsml:reuters.com:*:nGNX7W6wwC
    ** ALS is a nervous system disease that weakens muscles and
impacts physical function
    ** Additionally, ALS associated biomarkers were
significantly reduced in dose dependent manner - ELDN
    ** The 12-week trial included 54 patients with ALS at 13
treatment sites in the United States and Canada
    ** Stock has lost ~19% this year, as of last close
    

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))